2:30 – 3:30 pm Friday, September 4

Preparing Patients and Families for the Off-Therapy Transition (230)

Completion of cancer-directed therapy can be an exciting time for patients and their families but may also be anxiety provoking as they face a new set of challenges and a “new normal.” Patients may be returning to school with new needs for academic accommodations or returning to the care of their primary care provider, who may have limited experience with childhood cancer survivors.

Read more...
Speaker:
Emily Browne, DNP RN CPNP
CNE Hours
1
2:30 – 3:30 pm Friday, September 4

Below the Surface:  Applying Evidence-Based Practice in Skin Care Management with the Hematopoietic Cell Transplant Patient (229)

Children and adolescents undergoing hematopoietic cell transplant (HCT) are at high risk for developing skin complications. Nurses play a vital role in the assessment, prevention, and management of skin issues in this population where multiple factors lead to skin complications.

Read more...
Speaker:

Nancy Noonan, MS RN PCNS-BC BMTCN®

Linda Abramovitz, MSN RN CNS FAAN BMTCN®

Lisa Pinner, RN MSN CNS BMTCN® CPON® 

CNE Hours
1
2:30 – 3:30 pm Friday, September 4

This is Awkward...  Having Difficult Conversations about AYA Sexual Health (227)

Sexual and reproductive health (SRH) is a key aspect of physical health, emotional health, and quality of life in adolescents and young adults (AYAs) with cancer and blood disorders both during and after treatment. AYAs increasingly identify concerns with sexual function, contraception, fertility, and psychosexual adjustment and report conversations on these topics rarely take place with providers.

Read more...
Speaker:
Stacy Whiteside, MS APRN CPON® CPNP-AC/PC
CNE Hours
1
12:15 – 1:15 pm Friday, September 4

High Risk Neuroblastoma in the new decade: Incorporating targeted therapies to maximize impact in current Children’s Oncology Group trials (C226)

coglogoWhile the overall cure rate for childhood cancer is approaching 80%, the prognosis for long-term survival for children with high risk neuroblastoma lags considerably behind, at 50%–60%. Upfront standard treatment for high-risk neuroblastoma protocols within the Children’s Oncology Group (COG) has historically utilized all available modalities of cancer treatment including chemotherapy, surgery, myeloablative chemotherapy with stem cell rescue, radiation therapy, differentiating agents, and most recently biologic therapy with anti-GD2 antibody (dinutuximab) used post consolidation in ANBL0032.

Read more...
Speaker:

Wendy Fitzgerald, MSN APRN PPCNP-BC

Denise Mills, MN RN(EC) NP CPHON®

CNE Hours
1
9:30 – 10:30 am Friday, September 4

General Session: Gene Therapy and Gene Editing as a Treatment Option for Patients with Hemoglobinopathies (103)

Sickle cell disease is one of the most common inherited diseases in the Unites States, with a homozygous frequency of 1 in 400 African American births. The disease is associated with multiple complications including infections, veno-occlusive pain crisis, acute chest syndrome, and cerebrovascular accidents.

Read more...
Speaker:

Haydar Frangoul, MD MS

Misty Evans, DNP APRN CPNP-AC BMTCN®

CNE Hours
1
2:30 – 3:30 pm Thursday, September 3

Reproductive Health: from Diagnosis through Survivorship – Resources and Perspectives from the Children’s Oncology Group (C221)

coglogoPuberty and sexual and reproductive health are normal parts of human growth and development. Adolescence and young adulthood are developmental times of exploration of sexual identity and planning for the future, which may include parenting goals. A cancer diagnosis does not preclude a patient or their family from concern about sexual and reproductive health.

Read more...
Speaker:
Brooke Cherven, PhD MPH RN CPON®
Barbara Lockart, DNP APRN PC & AC CPHON®
CNE Hours
1
2:30 – 3:30 pm Thursday, September 3

Neurofibromatosis type 1 Diagnostic Updates and Plexiform Neurofibroma Treatment Options (218)

Neurofibromatosis (NF) 1 is a progressive autosomal dominant disorder that results from a germline mutation of a protein called neurofibromin that occurs in one out of every 3500 births (AANS, 2019). The clinical diagnosis of NF1 is based on the presence of two or more cardinal symptoms identified in the 1988 National Institute of Health (NIH) Diagnostic Criteria.

Read more...
Speaker:
Racheal Bingham, MSN CPNP CPON®
CNE Hours
1
12:15 – 1:15 pm Thursday, September 3

Cancer Control and Supportive Care in the Children’s Oncology Group: Nursing Roles and Recent Results (C215)

coglogoSurvival rates for many pediatric cancers have improved over time, although children and adolescents continue to experience acute and delayed toxicities related to their disease and treatment. This session will review the purpose and research domains within the Children’s Oncology Group (COG) Cancer Control (CCL) Committee.

Read more...
Speaker:
Jessica Ward, PhD MPH RN CPNP
Melissa Beauchemin, PhD RN CPNP CPON®
CNE Hours
1
Subscribe to this RSS feed